In the highly competitive and rapidly evolving biopharmaceutical landscape focused on RNA therapeutics and genetic medicines, Avidity Biosciences historically faced direct competition from several major biotech enterprises. Its primary rivals included Dyne Therapeutics, which also specializes in developing targeted oligonucleotide therapeutics for severe muscle diseases like Duchenne muscular dystrophy and myotonic dystrophy. Other prominent competitors in the broader RNA and precision medicine sector include Alnylam Pharmaceuticals, Ionis Pharmaceuticals, Wave Life Sciences, Arcturus Therapeutics, and BioNTech. These pioneering companies invest billions of dollars into advanced research and clinical trials, battling to overcome complex drug delivery challenges, secure regulatory approvals, and capture significant market share within the lucrative global landscape for rare genetic disorders and specialized targeted therapies.